Curated News
By: NewsRamp Editorial Staff
November 07, 2025
Soligenix Reports Q3 Progress, Key Milestones for Rare Disease Treatments
TLDR
- Soligenix's upcoming Phase 2a psoriasis results and Phase 3 CTCL trial progress offer potential investment advantages in the rare disease biopharmaceutical sector.
- Soligenix reported Q3 2025 results with $10.5 million cash extending operations through 2026 while advancing Phase 2a and Phase 3 clinical trials.
- Soligenix's treatments for rare diseases like CTCL and psoriasis address unmet medical needs, potentially improving patient outcomes and quality of life worldwide.
- Soligenix uses novel photodynamic therapy with safe visible light to treat CTCL, representing an innovative approach in biopharmaceutical development.
Impact - Why it Matters
This development matters because Soligenix is advancing treatments for rare diseases that currently lack effective therapeutic options. The progress in HyBryte™ for cutaneous T-cell lymphoma represents a potential breakthrough for patients suffering from this rare cancer who have limited treatment alternatives. The expansion into psoriasis treatment with SGX302 could benefit millions of patients worldwide who struggle with this chronic inflammatory condition. Additionally, the company's vaccine development programs address critical public health threats including ricin exposure, filoviruses like Ebola and Marburg, and COVID-19 variants. For investors, Soligenix's strong cash position and extended operational runway through 2026 provide stability while the company advances multiple late-stage clinical programs that could deliver significant value if approved.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical needs, reported significant progress in its third quarter 2025 results. Under the leadership of CEO Christopher J. Schaber, PhD, the company announced upcoming milestones including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte™ study in cutaneous T-cell lymphoma (CTCL). The first Data Monitoring Committee review for HyBryte™ revealed no safety concerns, maintaining the treatment's consistent safety profile across clinical trials. With $10.5 million in cash as of September 30, 2025, Soligenix expects its operating runway to extend through 2026 while evaluating strategic options to advance its late-stage pipeline.
The company's Specialized BioTherapeutics segment is advancing multiple innovative treatments, including HyBryte™ (SGX301), a novel photodynamic therapy using safe visible light for CTCL treatment. Following successful completion of the second Phase 3 study, Soligenix plans to seek regulatory approvals worldwide. Additional development programs include expanding synthetic hypericin (SGX302) into psoriasis treatment, first-in-class innate defense regulator technology with dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease. The company's Public Health Solutions segment, supported by government funding from agencies including NIAID, DTRA, and BARDA, focuses on vaccine development incorporating the proprietary ThermoVax® heat stabilization platform technology.
This news was distributed through the InvestorBrandNetwork's Dynamic Brand Portfolio, which provides advanced wire-grade press release syndication and comprehensive corporate communications solutions. The full details of Soligenix's progress and financial position are available in their comprehensive newsroom, offering investors and stakeholders complete access to the latest developments from this innovative biopharmaceutical company dedicated to addressing critical unmet medical needs in rare diseases and public health threats.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Reports Q3 Progress, Key Milestones for Rare Disease Treatments
